GARDASIL


Pre-filled syringe 1
scheduling status
S2
registration number
41/30.1/0145
What GARDASIL is and what it is used for
GARDASIL is a vaccine indicated in girls and women 9 through 45 years for the prevention of cervical, vulvar, vaginal and anal cancer, pre-cancerous or dysplastic lesions, genital warts and infections caused by the Human Papillomavirus (HPV). GARDASIL is indicated to prevent the following diseases: • Cervical, vulvar, vaginal and anal cancer caused by HPV types 16 and 18. • Genital warts (condyloma acuminata) caused by HPV 6 and 11. And infections and the following pre-cancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18: • Cervical intraepithelial neoplasia (CIN) grade 2 and 3 and Cervical adenocarcinoma in situ (AIS). • Cervical intraepithelial neoplasia (CIN) grade 1. • Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3. • Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3. • VIN grade 1 and VaIN grade 1. • Anal intraepithelial neoplasia (AIN) grades 1, 2 and 3. GARDASIL also provides protection in girls and women 9 through 26 years of age against HPV 31-, 33-, 52- and 58-related CIN grades. GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of external genital lesions and infection and the following diseases caused by HPV types included in the vaccine: • Anal cancer caused by HPV types 16 and 18. • Genital warts (condyloma acuminata) caused by HPV types 6 and 11. And the following pre-cancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18: • Anal intraepithelial neoplasia (AIN) grades 1, 2 and 3.
dosage
GARDASIL should be administered intramuscularly as 3 separate 0,5 ml doses according to the following schedule: First dose: At elected date. Second dose: 2 months after the first dose. Third dose: 6 months after the first dose.
how to take
GARDASIL should be administered intramuscularly in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. GARDASIL must not be injected intravascularly. Neither subcutaneous nor intradermal administration has been studied. These methods of administration are not recommended. The pre-filled syringe is for single use only and should not be used for more than one individual. The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used.
What GARDASIL contains
Each 0,5 ml dose contains approximately 20 mcg of Human Papillomavirus (HPV) 6 L1 protein, 40 mcg of HPV 11 L1 protein, 40 mcg of HPV 16 L1 protein, and 20 mcg of HPV 18 L1 protein.
other ingredients
225 mcg of aluminium (as amorphous aluminium hydroxyphosphate sulphate adjuvant), 9,56 mg of sodium chloride, 0,78 mg of L-histidine, 50 mcg of polysorbate 80 and 35 mcg of sodium borate. The product does not contain a preservative or antibiotics.
Therapeutic classification
A. 30.1 Biologicals - Antigens.
© 2026 SAHPRA. ALL RIGHTS RESERVED